Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves.

Yoon IK, Choi YJ, Chang BC, Lee KE, Rhie JY, Lee BK, Gwak HS.

Arch Pharm Res. 2014 Jun;37(6):752-9. doi: 10.1007/s12272-013-0221-4. Epub 2013 Aug 2.

PMID:
23907550
2.

Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.

Lee KE, Chang BC, Kim HO, Yoon IK, Lee NR, Park HY, Gwak HS.

Ther Drug Monit. 2012 Jun;34(3):275-82. doi: 10.1097/FTD.0b013e318256a77c.

PMID:
22549502
3.

Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients.

Cho HJ, Sohn KH, Park HM, Lee KH, Choi B, Kim S, Kim JS, On YK, Chun MR, Kim HJ, Kim JW, Lee SY.

Pharmacogenomics. 2007 Apr;8(4):329-37.

PMID:
17391071
4.

Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses.

Moon JY, Chang BC, Lee KE, Bang JS, Gwak HS.

J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):532-8. doi: 10.1177/1074248415578906. Epub 2015 Apr 6.

PMID:
25848132
5.

Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.

Chung JE, Chang BC, Lee KE, Kim JH, Gwak HS.

Eur J Clin Pharmacol. 2015 Oct;71(10):1229-36. doi: 10.1007/s00228-015-1915-y. Epub 2015 Aug 11.

PMID:
26257249
6.

Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.

Yang L, Ge W, Yu F, Zhu H.

Thromb Res. 2010 Apr;125(4):e159-66. doi: 10.1016/j.thromres.2009.10.017. Epub 2009 Nov 25. Review.

PMID:
19942260
7.

Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese.

Zeng WT, Xu Q, Li CH, Chen WY, Sun XT, Wang X, Yang YY, Shi H, Yang ZS.

Eur J Clin Pharmacol. 2016 Nov;72(11):1327-1334. Epub 2016 Aug 4.

PMID:
27488389
8.

A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS, Shin JG.

Br J Clin Pharmacol. 2010 Aug;70(2):213-21. doi: 10.1111/j.1365-2125.2010.03688.x.

9.

Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial.

Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q.

Int J Med Sci. 2012;9(6):472-9. doi: 10.7150/ijms.4637. Epub 2012 Aug 10.

10.

Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients.

Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA.

Pharmacotherapy. 2011 Aug;31(8):785-92. doi: 10.1592/phco.31.8.785.

PMID:
21923605
11.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
12.

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H.

Clin Pharmacol Ther. 2003 Mar;73(3):253-63.

PMID:
12621390
13.

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.

Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM.

Clin Pharmacol Ther. 2004 Mar;75(3):198-203.

PMID:
15001971
14.

The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement.

Tang XY, Zhang J, Peng J, Tan SL, Zhang W, Song GB, Liu LM, Li CL, Ren H, Zeng L, Liu ZQ, Chen XP, Zhou XM, Zhou HH, Hu JX, Li Z.

J Clin Pharm Ther. 2017 Aug;42(4):438-445. doi: 10.1111/jcpt.12527. Epub 2017 Apr 21.

PMID:
28429387
15.

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC.

Ther Drug Monit. 2010 Jun;32(3):338-45. doi: 10.1097/FTD.0b013e3181d925bb.

PMID:
20386359
16.

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H.

Clin Pharmacol Ther. 2004 Mar;75(3):204-12.

PMID:
15001972
17.

Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves.

Jeong E, Lee KE, Jeong H, Chang BC, Gwak HS.

Pharmacogenomics J. 2015 Feb;15(1):33-7. doi: 10.1038/tpj.2014.36. Epub 2014 Jul 15.

PMID:
25026456

Supplemental Content

Support Center